ORIGIN® vs. VANGUARD® PS Observational Study
Launched by SYMBIOS ORTHOPEDIE SA · Jan 24, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The ORIGIN® vs. VANGUARD® PS Observational Study is examining how satisfied patients are after knee replacement surgery using two different types of implants. One implant is custom-made for each patient (ORIGIN®), while the other is a standard, off-the-shelf option (VANGUARD PS). The goal is to see how well these devices perform in real-life hospital settings and to understand their impact on patient satisfaction after surgery.
If you're between the ages of 65 and 74 and are considering knee replacement surgery, you may be eligible to participate in this study. Participants will have the opportunity to share their experiences and help researchers learn more about which type of implant may be better for patients. The study is currently recruiting participants, and anyone in this age group who has undergone or is planning to undergo knee replacement surgery can consider joining. Your input could help improve future treatments for others!
Gender
ALL
Eligibility criteria
- • Inclusion/exclusion criteria
About Symbios Orthopedie Sa
Symbios Orthopedie SA is a leading medical device company specializing in innovative orthopedic solutions. With a commitment to enhancing patient outcomes, the company focuses on the development and commercialization of advanced implants and surgical instruments that facilitate orthopedic procedures. Leveraging cutting-edge technology and extensive clinical research, Symbios Orthopedie SA aims to provide healthcare professionals with reliable tools that promote effective healing and rehabilitation. The organization is dedicated to quality, safety, and efficacy, ensuring that its products meet the highest standards in the orthopedic industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mainz, , Germany
Mainz, , Germany
Patients applied
Trial Officials
Philippe Drees, Prof
Principal Investigator
Johannes Gutenberg University Mainz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials